Shanghai Celgen Biopharma Co., Ltd.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shanghai Celgen Biopharma Co., Ltd.
Celltrion Gets Go-Ahead For Remsima Trials In China, Mulls JV
Celltrion has received approval to begin clinical trials of its biosimilar infliximab in China and also filed IND applications for other biosimilar products with the CFDA, accelerating plans to enter the world’s second biggest pharma market as it propels efforts for global leadership in the biosimilar space.
Celltrion Gets Go-Ahead For Remsima Trials In China, Mulls JV
Celltrion has received approval to begin clinical trials of its biosimilar infliximab in China and also filed IND applications for other biosimilar products with the CFDA, accelerating plans to enter the world’s second biggest pharma market as it propels efforts for global leadership in the biosimilar space.
BMS Tests Virtual R&D Network In China For Orencia Deal With Simcere
BMS has been trying since 2012 to figure out a way to bring its first biologic product to China. Now, the company will partner with Simcere to hasten development of its $1.2 billion rheumatoid arthritis blockbuster Orencia.
BMS Tests Virtual R&D Network In China For Orencia Deal With Simcere
BMS has been trying since 2012 to figure out a way to bring its first biologic product to China. Now, the company will partner with Simcere to hasten development of its $1.2 billion rheumatoid arthritis blockbuster Orencia.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice